Bill Booth kindly invited me on to his podcast to discuss health and medicine. Bill is one of the founders of Radical Americas, an academic network for scholars and activists with interests in radicalism in the Western Hemisphere.
The ADHS is pleased to announce that the editorship of its journal, *The Social History of Alcohol and Drugs*, will be taken over by Prof. Nancy D. Campbell (Rensselaer Polytechnic Institute), Prof. David Herzberg (Buffalo) and Dr. Lucas Richert (Strathclyde). The society would also like to express its gratitude for the work that outgoing editor, […]
The ADHS is excited to announce that its next bi-annual conference will be held between 12 and 15 June 2019, at the David F. Musto Center for Drug Policy Studies, Shanghai University, China. The conference will be organised by Prof. Jim Mills, of the University of Strathclyde and Prof. Yong-an Zhang of Shanghai University, who […]
Today, historians begin descending upon wintry Washington, D.C., for the 2018 meeting of the American Historical Association. AHA is the largest annual gathering for such professionals and their affiliated societies. Among those represented again this year is the Alcohol and Drugs History Society, with two panels of original research and one roundtable discussion. The date, […]
Sara Pascoe on resolutions
For me it was a slang phrase that ruined it. A man was talking, and I was listening politely because he was a friend of a friend. “Friend of a friend” is an excellent expression, it passively clarifies: “I know them … but I don’t like them”. An “acquaintance” is someone we haven’t decided if we like or not yet. An “associate” is a drug dealer. A “friend of a friend” is an idiot at a party you must tolerate because apparently I can’t fulfil all Rebecca’s friending needs and she wants gatherings to be full of people from work and their boyfriends. This one was telling me that he wouldn’t move over from Sydney because that’s where his mates are. “Bros before hoes,” he says. A saying I thought even the most hardened misogynist used ironically. Of course, I admire the sentiment, saving our loyalty for friends over those we must tolerate because our genitals want to get to know them. But I was shocked that someone would speak like this. We were in a kitchen, not a poorly written sitcom. And then I became sad as I was reminded once again about the gulf of understanding that can exist between human beings even if they have a friend in common. And so already 2018 was ruined. Fifty-two minutes in.
When did yours go wrong? I wonder if you felt annoyed for expecting anything to be different? It all started out great with hugging and music, then at 1am you saw the Uber surge price was in double figures and wept as you realised: it got me again. Hope. We think newness can save us, we don’t realise that we haven’t changed – only the date has.
RADICAL TEMPERANCE: SOCIAL CHANGE AND DRINK, FROM TEETOTALISM TO DRY JANUARY UNIVERSITY OF CENTRAL LANCASHIRE, PRESTON, 28-29 JUNE 2018 FEATURING KEYNOTE ADDRESSES BY: Professor Scott Martin, Bowling Green University, Ohio Professor Betsy Thom, Middlesex University This conference seeks to explore the radical aspects of the avoidance of alcohol. We are looking for contributions […]
I wrote about Lambert Publishers last month. And they’ve come back at me again. They want to publish an article of mine. Lambert is, of course, a ‘predatory publisher,’ and the company is all about cashing in on other’s work.
Here’s what they wrote me earlier this month.
Again, I went to school for a long f****** time. I’m not super uptight about it, but get the salutation correct.
I’m told I should have some questions…why? Because publishing – i.e., with Lambert – is a major achievement. Love it.
I also love the closing line. All of us in this hyper competitive dog-eat-dog academic world find publishing “interesting.” Seriously.
Lambert is an interesting company…watch out.
Here’s another interesting Lambert.
A lot happened in the world of pharmaceuticals this year. The opioid crisis worsened. The FDA got a new chief. There were big failures and prices reemerged as a major issue. Industry needed to contend with the new Trump administration and gene therapy ‘came of age.’
By the way, here is one year in review article that showcases some of these ideas:
The following article is a short version of BP Round-up. Why? Happy New Year and Hogmanay!
Let’s start with cannabis:
Money-making? Here are some tips and stories:
Also, I’ll be speaking in Glasgow about Big Pharma and other topics on January 22nd.
Here is a snapshot of the past week in Big Pharma news. This is coming at you a little early because of the Christmas slowdown. Happy holidays.
To kick off:
The drug industry spent big!
Here’s another one on the lobbying money spent over the past months and years…
A lot of money was splashed out. ‘“Does that surprise you?” said Billy Tauzin, the former PhRMA CEO who ran the organization a decade ago as Obamacare loomed. Whenever Washington seems interested in limiting drug prices, he said, “PhRMA has always responded by increasing its resources.”’
In Canada, there’s efforts to reduce “sticker shock” when purchasing drugs.
“A Toronto family doctor thinks she has a prescription for the nasty surprise many patients experience when they go to the pharmacy and learn just how much their medications will cost.”
What about other countries besides the US? Say, Poland. It spends a lot on pharmaceuticals – but on the right drugs?
Then, more on opioids. Ravaged by Opioids!
Away from the young, and to the old: could drugs slow ageing?
“Some pharmaceutical companies are exploring whether [certain] genetic traits could be used to create anti-ageing drugs.”
And in BC, Canada: illicit placenta and stem cell therapies were seized!!!
‘The drugs confiscated from Before & After Beauty Lab on Hazelbridge Way “may pose serious risks to health,” according to a Health Canada press release.’
There was a also mysterious double murder in the world of Big Pharma!
Here at Strathclyde, CMAC welcomes Pfizer as newest partner…
“CMAC (Continuous Manufacturing and Advanced Crystallisation), a pre-competitive consortium led by the University of Strathclyde to accelerate progress in pharmaceutical manufacturing, announces that Pfizer Inc has joined as a strategic member, alongside GSK, AZ, Novartis, Bayer, Takeda, Lilly and Roche.”
Lastly, St Thomas University (Canada) is hiring a cannabis/marijuana scholar. As the cannabis industry consolidates and the medicine is refined further, the job is a useful chance to contribute to the discussion. And it looks spectacular.
Here is a flyer for my book on Big Pharma! Cheap, cheap, cheap.